lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
December 30, 2025
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
December 15, 2025
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
December 12, 2025
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
December 11, 2025
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
November 29, 2025
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
November 21, 2025
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
November 8, 2025
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
October 31, 2025
←
Previous Page
1
2